The Patent Finder
KT

Kymera Therapeutics, Inc.

First filing 2018
OverviewNotableFeesChangesFamiliesPatent listSources & methods

50 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Oct 2038. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2038
Next term end
32
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Irak Degraders and Uses Thereof US 10,874,743
The most cited patent in this portfolio, cited by 71 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2038.
Ends Dec 2038 · High confidence
Also notable
Protein Degraders and Uses Thereof US 11,485,743
Cited by 35 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2039.
Ends Jan 2039 · High confidence
Also notable
Irak Degraders and Uses Thereof US 11,352,350
Cited by 26 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2039.
Ends Dec 2039 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 20 to 27, 2026 · next Dec 20
  • 1 fee due Jan 25, 2027
    The maintenance fee for Irak Degraders and Uses Thereof (US 11,707,457) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
  • 1 fee due Feb 15, 2027
    The maintenance fee for Irak Degraders and Uses Thereof (US 11,723,980) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
  • 1 fee due Mar 5, 2027
    The maintenance fee for Stat Degraders and Uses Thereof (US 11,746,120) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
  • 2 fees due Apr 3 to 10, 2027 · next Apr 3
  • 1 fee due May 7, 2027
    The maintenance fee for Irak Degraders and Uses Thereof (US 11,807,636) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
  • 1 fee due Jul 2, 2027
    The maintenance fee for Methods of Treating Mutant Lymphomas (US 11,857,535) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 1 fee due Aug 13, 2027
    The maintenance fee for Tricyclic CRBN Ligands and Uses Thereof (US 11,897,882) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
  • 2 fees due Sep 19, 2027

Which patents, and when each one lapses · Pro

Recent changes

  • 4 of the patents on this record were granted since Aug 22, 2026

What they patent

The largest of its 32 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 11,358,948CRBN Ligands and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,874,743Irak Degraders and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,318,205Irak Degraders and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,723,980Irak Degraders and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 12,168,057Irak Degraders and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 11,623,932Protein Degraders and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,485,743Protein Degraders and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,932,635CRBN Ligands and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 12,006,329Protein Degraders and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 12,516,068Protein Degraders and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
10 of 50 patents shown.
Pro members see all 50.
Pro members: see all 50 patents
Also on record, not counted in the 50: 58 applications pending · 22 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited